Molecular Cancer Therapeutics
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Okouneva, T.
Right arrow Articles by Jordan, M. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Okouneva, T.
Right arrow Articles by Jordan, M. A.
Vol. 2, 427-436, May 2003     Molecular Cancer Therapeutics
© 2003 American Association for Cancer Research

The Effects of Vinflunine, Vinorelbine, and Vinblastine on Centromere Dynamics1

Tatiana Okouneva, Bridget T. Hill, Leslie Wilson and Mary Ann Jordan2

Department of Molecular, Cellular, and Developmental Biology University of California Santa Barbara, Santa Barbara, California 93106 [T. O., L. W., M. A. J.], and Centre de Recherche Pierre Fabre, 81106 Castres Cedex, France [B. T. H.]

2 To whom requests for reprints should be addressed, at Department of Molecular, Cellular, and Developmental Biology, University of California Santa Barbara, Santa Barbara, CA 93106. Phone: (805) 893-5317; Fax: (805) 893-4724; E-mail: jordan{at}lifesci.ucsb.edu

Vinflunine is a novel fluorinated Vinca alkaloid currently in Phase II clinical trials, which in preclinical studies exhibited superior antitumor activity to that of two clinically useful Vinca alkaloids, vinorelbine and vinblastine. All three of the drugs block mitosis at the metaphase/anaphase transition, leading to apoptosis. The mechanism of the mitotic block is not known. On the basis of results with purified microtubules and in living interphase cells, we hypothesized that it involves suppression of spindle microtubule dynamics. Here we measured the effects of the three Vinca alkaloids on dynamics of centromeres and spindle kinetochore-microtubules by a novel approach involving quantitative time-lapse confocal microscopy in living mitotic human U2OS cells. Green fluorescent protein-labeled centromere-binding protein B was used to mark centromeres and kinetochore-microtubule plus ends. In controls, pairs of centromeres on sister chromatids alternated under tension between increasing and decreasing separation (stretching and relaxing). All three of the Vinca alkaloids suppressed centromere dynamics similarly at concentrations that block mitosis. At concentrations approximating the IC50s for mitotic accumulation (18.8 nM vinflunine, 7.3 nM vinorelbine, and 6.1 nM vinblastine), centromere dynamicity decreased by 44%, 25%, and 26%, respectively, and the time centromeres spent in a paused state increased by 63%, 52%, and 36%, respectively. Centromere relaxation rates, stretching durations, and transition frequencies all decreased. Thus all three of the drugs decreased the normal microtubule-dependent spindle tension at the centromeres/kinetochores, thereby preventing the signal for mitotic checkpoint passage. The strong correlation between suppression of kinetochore-microtubule dynamics and mitotic block indicates that the primary mechanism by which the Vinca alkaloids block mitosis is suppression of spindle microtubule dynamics.




This article has been cited by other articles:


Home page
Molecular Cancer TherapeuticsHome page
T. Okouneva, O. Azarenko, L. Wilson, B. A. Littlefield, and M. A. Jordan
Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase
Mol. Cancer Ther., July 1, 2008; 7(7): 2003 - 2011.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
J. Bennouna, J.-P. Delord, M. Campone, and L. Nguyen
Vinflunine: A New Microtubule Inhibitor Agent
Clin. Cancer Res., March 15, 2008; 14(6): 1625 - 1632.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
M.-A. Esteve, M. Carre, V. Bourgarel-Rey, A. Kruczynski, G. Raspaglio, C. Ferlini, and D. Braguer
Bcl-2 down-regulation and tubulin subtype composition are involved in resistance of ovarian cancer cells to vinflunine.
Mol. Cancer Ther., November 1, 2006; 5(11): 2824 - 2833.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
C. Cunningham, L. J. Appleman, M. Kirvan-Visovatti, D. P. Ryan, E. Regan, S. Vukelja, P. L. Bonate, F. Ruvuna, R. J. Fram, A. Jekunen, et al.
Phase I and Pharmacokinetic Study of the Dolastatin-15 Analogue Tasidotin (ILX651) Administered Intravenously on Days 1, 3, and 5 Every 3 Weeks in Patients with Advanced Solid Tumors
Clin. Cancer Res., November 1, 2005; 11(21): 7825 - 7833.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
M. A. Jordan, K. Kamath, T. Manna, T. Okouneva, H. P. Miller, C. Davis, B. A. Littlefield, and L. Wilson
The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth
Mol. Cancer Ther., July 1, 2005; 4(7): 1086 - 1095.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
Z. Chen, P. J. Merta, N.-H. Lin, S. K. Tahir, P. Kovar, H. L. Sham, and H. Zhang
A-432411, a novel indolinone compound that disrupts spindle pole formation and inhibits human cancer cell growth
Mol. Cancer Ther., April 1, 2005; 4(4): 562 - 568.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
S. Honore, K. Kamath, D. Braguer, L. Wilson, C. Briand, and M. A. Jordan
Suppression of microtubule dynamics by discodermolide by a novel mechanism is associated with mitotic arrest and inhibition of tumor cell proliferation
Mol. Cancer Ther., December 1, 2003; 2(12): 1303 - 1311.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2003 by the American Association for Cancer Research.